Welcome to our dedicated page for CALCIMEDICA SEC filings (Ticker: CALC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CalciMedica, Inc. (CALC) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, clinical-stage biopharmaceutical company focused on CRAC channel inhibition therapies, CalciMedica uses its filings to report financial results, corporate actions, and material developments related to programs such as its Auxora™ clinical trials in acute kidney injury (AKI) with respiratory failure and acute pancreatitis (AP).
Key documents available through EDGAR and summarized here include Form 10-K annual reports and Form 10-Q quarterly reports, which provide detailed discussions of CalciMedica’s business, risk factors, pipeline status, and financial condition. Form 8-K current reports capture specific events such as quarterly earnings press releases, amendments to equity incentive plans approved at the annual meeting, and changes to at-the-market equity offering capacity under the company’s agreement with H.C. Wainwright & Co.
Investors can also monitor S-3 and S-8 registration statements and related exhibits that describe securities offerings and share-based compensation plans, as well as any Form 4 insider transaction reports that may be filed by directors and officers. These filings help clarify how CalciMedica finances its clinical-stage operations, including the use of at-the-market offerings and a disclosed credit facility, and how equity incentives are structured for employees and leadership.
Stock Titan enhances access to these documents with AI-powered summaries that highlight key points from lengthy filings, such as changes in cash runway commentary, updates on the KOURAGE trial, or modifications to capital-raising programs. Real-time updates from EDGAR ensure that new CalciMedica filings appear quickly, while structured views of 10-Ks, 10-Qs, 8-Ks, registration statements, and Form 4 reports allow users to focus on the specific regulatory information most relevant to their analysis of CALC.
CalciMedica, Inc. reported an insider share purchase by an account associated with its chief business officer and director Eric W. Roberts. On August 15, 2025, a Roth IRA account held at FMTC Custodian for his benefit bought 5,076 shares of CalciMedica common stock in an open‑market transaction at a weighted average price of $2.8977 per share, with individual trade prices ranging from $2.80 to $2.90.
After this transaction, that Roth IRA account held 54,399 CalciMedica shares. The filing also reports 164,706 shares held directly and additional indirect holdings through other Roth IRA and investment entities associated with Roberts.
CalciMedica, Inc. (CALC) reporting person Hebbar Sudarshan, the company's Chief Medical Officer, purchased additional common stock in two transactions. On 08/14/2025 he acquired 1,584 shares at a weighted average price of $2.585, bringing his direct beneficial ownership to 47,584 shares. On 08/15/2025 he acquired 4,392 shares at a weighted average price of $2.793, increasing his direct ownership to 51,976 shares. The filing was signed by an attorney-in-fact on 08/18/2025. The filing includes price ranges for the trades and notes that detailed per-price purchase counts are available on request.
CalciMedica, Inc. filed a Form 8-K reporting that on August 12, 2025 it issued a press release announcing financial results for the fiscal quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and the filing also includes an Inline XBRL cover page as Exhibit 104. The company states the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and therefore is not subject to certain liabilities under the federal securities laws.
The report is signed by CEO A. Rachel Leheny, Ph.D.. The filing confirms the Nasdaq ticker CALC and that the registrant identified itself as an emerging growth company.
CalciMedica, Inc. (CALC) – Form 4 filed 10 Jul 2025
Chief Business Officer, Director and 10% owner Eric W. Roberts reported an open-market purchase of 5,000 common shares on 09 Jul 2025 at $1.6047 per share. After the transaction, he beneficially owns roughly 1,002,410 CALC shares distributed across direct holdings (164,706 shares), several Roth/Traditional IRAs and three Valence Investments SPVs, the largest of which holds 356,989 shares. No derivative securities were transacted in this filing.
The acquisition marginally increases Roberts’ stake by about 0.5% and may signal incremental confidence, though the dollar value is modest relative to his existing position.
On 07/01/2025, CalciMedica, Inc. (ticker CALC) filed a Form 4 disclosing that its Chief Scientific Officer, Kenneth A. Stauderman, executed a single open-market purchase marked with transaction code “P.” The transaction, carried out through his spouse’s account, involved 1,000 shares of CalciMedica common stock at a price of $1.85 per share, for an aggregate cost of roughly $1,850. Following the purchase, Stauderman reports indirect beneficial ownership of the 1,000 newly acquired shares and direct ownership of 11,944 shares. No derivative transactions were reported, and the filing is made solely by one reporting person. The form does not indicate use of a Rule 10b5-1 plan.